About Rigel

Company Overview

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. Rigel has a history deeply rooted in scientific innovation and investing in novel approaches to drug discovery and development.

Our business strategy is to transition to a commercial-stage company with our Phase 3 results from fostamatinib in immune thrombocytopenic purpura (ITP). We continue to build an extensive portfolio of products in immunology and oncology, monetizing select assets through attractive partnerships.

Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company completed and reported results from the FIT Phase 3 clinical program of fostamatinib in chronic/persistent immune thrombocytopenia, or ITP. These data will serve as the basis for a New Drug Application that the company plans to submit to the U.S. Food and Drug Administration in the first quarter of 2017. The investigation of fostamatinib also includes a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA) and a Phase 2 clinical trial for IgA Nephropathy. In addition, Rigel has two oncology product candidates in development with partners BerGenBio AS (Phase 2) and Daiichi Sankyo (Phase 1).